http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shim, Hyoeun,Ha, Joo Hee,Lee, Hyewon,Sohn, Ji Yeon,Kim, Hyun Ju,Eom, Hyeon-Seok,Kong, Sun-Young Hindawi Publishing Corporation 2014 BioMed research international Vol.2014 No.-
<P>We evaluated the association between the expression of myeloid antigens on neoplastic plasma cells and patient prognosis. The expression status of CD13, CD19, CD20, CD33, CD38, CD56, and CD117 was analyzed on myeloma cells from 55 newly diagnosed patients, including 36 men (65%), of median age 61 years (range: 38–78). Analyzed clinical characteristics and laboratory parameters were as follows: serum <I><I>β</I></I>2-microglobulin, lactate dehydrogenase, calcium, albumin, hemoglobin, serum creatinine concentrations, bone marrow histology, and cytogenetic findings. CD13+ and CD33+ were detected in 53% and 18%, respectively. Serum calcium (<I>P</I> = 0.049) and LDH (<I>P</I> = 0.018) concentrations were significantly higher and morphologic subtype of immature or plasmablastic was more frequent in CD33+ than in CD33− patients (<I>P</I> = 0.022). CD33 and CD13 expression demonstrate a potential prognostic impact and were associated with lower overall survival (OS; <I>P</I> = 0.001 and <I>P</I> = 0.025) in Kaplan-Meier analysis. Multivariate analysis showed that CD33 was independently prognostic of shorter progression free survival (PFS; <I>P</I> = 0.037) and OS (<I>P</I> = 0.001) with correction of clinical prognostic factors. This study showed that CD13 and CD33 expression associated with poor prognosis in patients with MM implicating the need of analysis of these markers in MM diagnosis.</P>
Lee, Hyewon,Kong, Sun-Young,Sohn, Ji Yeon,Shim, Hyoeun,Youn, Hye Sun,Lee, Sangeun,Kim, Hyun Ju,Eom, Hyeon-Seok Hindawi Publishing Corporation 2014 BioMed research international Vol.2014 No.-
<P>Red blood cell distribution width (RDW) is a parameter reported in complete blood cell count tests, and has been reported as an inflammatory biomarker. Multiple myeloma (MM) is known to be associated with inflammatory microenvironments. However, the importance of RDW has been seldom studied in MM. For this study, 146 symptomatic myeloma patients with available RDW at diagnosis were retrospectively reviewed, and their characteristics were compared between two groups, those with high (>14.5%) and normal (≤14.5%) RDW. RDW was correlated to hemoglobin, MM stage, <I><I>β</I></I>2-microglobulin, M-protein, bone marrow plasma cells, and cellularity (<I>P</I> < 0.001). During induction, overall response rates of the two groups were similar (<I>P</I> = 0.195); however, complete response rate was higher in the normal-RDW group than it was in the high-RDW group (<I>P</I> = 0.005). With a median follow-up of 47 months, the normal-RDW group showed better progression-free survival (PFS) (24.2 versus 17.0 months, <I>P</I> = 0.029) compared to the high-RDW group. Overall survival was not different according to the RDW level (<I>P</I> = 0.236). In multivariate analysis, elevated RDW at diagnosis was a poor prognostic factor for PFS (HR 3.21, 95% CI 1.24–8.32) after adjustment with other myeloma-related prognostic factors. RDW would be a simple and immediately available biomarker of symptomatic MM, reflecting the systemic inflammation.</P>